Skip to main content
NCBI home page
Radiation Oncology (London, England) logoLink to Radiation Oncology (London, England)
. 2020 Dec 14;15:280. doi: 10.1186/s13014-020-01708-y

Correction to: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy

Melanoma brain metastases prognostic score

Jana Schaule 1,2,✉,#, Stephanie G C Kroeze 1,#, Oliver Blanck 3, Susanne Stera 4, Klaus H Kahl 5, Falk Roeder 6, Stephanie E Combs 7,8,9, David Kaul 10, An Claes 11, Markus M Schymalla 12, Sonja Adebahr 13,14,15, Franziska Eckert 16, Fabian Lohaus 15,17,18, Nasrin Abbasi-Senger 19, Guido Henke 20, Marcella Szuecs 21, Michael Geier 22, Nora Sundahl 23, Daniel Buergy 24, Reinhard Dummer 25, Matthias Guckenberger 1
PMCID: PMC7734768  PMID: 33317582

Correction to: Radiation Oncology(2020) 15:135 https://doi.org/10.1186/s13014-020-01558-8

Following publication of the original article [1], we have been notified that there is a mistake in the affiliations of authors initially mentioned. Correct affiliations of the authors are provided in this article.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Jana Schaule and Stephanie G. C. Kroeze contributed equally to this work.

Reference

  • 1.Schaule, et al. Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy. Melanoma brain metastases prognostic score. Radiat Oncol. 2020;15:135. doi: 10.1186/s13014-020-01558-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Radiation Oncology (London, England) are provided here courtesy of BMC

RESOURCES